Fosun Pharma Subsidiary’s Lung Cancer Drug Application Accepted by China Regulator

An announcement from Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) is now available.

Shanghai Fosun Pharmaceutical announced that its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group has had its resubmitted drug registration application for Foritinib Succinate Capsules accepted by China’s National Medical Products Administration. The innovative small-molecule chemical drug, classified as a Class 1 chemical medicine, is being developed to treat patients with ALK-positive locally advanced or metastatic non-small cell lung cancer, while a separate indication for ROS1-positive non-small cell lung cancer has already completed Phase II clinical trials in China. The acceptance of this application underscores Fosun Pharma’s push in innovative oncology therapies and, if successfully approved, could strengthen its position in China’s lung cancer treatment market and enhance its oncology portfolio.

The most recent analyst rating on (HK:2196) stock is a Hold with a HK$20.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based pharmaceutical group engaged in the research, development, manufacturing and commercialization of innovative drugs and other healthcare products. Through subsidiaries such as Fosun Wanbang (Jiangsu) Pharmaceutical Group, the company focuses on prescription medicines, particularly in oncology and other high-burden disease areas, targeting both domestic and international markets.

Average Trading Volume: 4,616,289

Technical Sentiment Signal: Buy

Current Market Cap: HK$76.02B

Learn more about 2196 stock on TipRanks’ Stock Analysis page.